Abstract
Pancreatic neuroendocrine tumors (pNET) are rare neoplasms, occurring in less than 1 out of 100,000 people per year and representing 1-2% of all pancreatic tumors. While resection is the only curative treatment for localized disease, it remains a debated management option as many low-grade and intermediate-grade tumors have indolent clinical courses. We reviewed our tertiary center’s large experience of nonfunctioning pNETs and assessed the diagnostic yield of EUS-FNA with respect to Ki-67 index, tumor size, mitotic rate, lymph node involvement (LN+), lymphovascular invasion (LVI+) or other invasive features (peripancreatic fat, neural, perineural, splenic or duodenal invasion) at the time of surgical resection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
